Aerie Pharmaceuticals to Announce Fourth Quarter and Full Year 2021 Financial Results and Host Conference Call on Thursday, February 24, 2022 at 5:00 p.m. ET
Following the release, Aerie will host a live conference call and webcast at 5:00 p.m. Eastern Time to discuss Aerie’s financial results and provide a general business update.
Details: | ||
Date: |
February 24, 2022 |
|
Conference call Time: |
5:00 p.m. ET |
|
Suggested Dial-in Time |
15 minutes prior to ensure time for any required software download |
|
Webcast: |
||
US Dial-In option |
(888) 734-0328 |
|
International Dial-In option |
(678) 894-3054 |
|
Conference ID |
3766969 |
|
Replay (2h post call) |
(855) 859-2056 (U.S.) or (404) 537-3406 (international) |
|
Replay ID |
3766969 |
|
Replay Availability |
Until March 4, 2022 |
About Aerie Pharmaceuticals, Inc.
Aerie is a pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with eye diseases and conditions including open-angle glaucoma, dry eye, diabetic macular edema (DME) and wet age-related macular degeneration (wet AMD). Aerie’s first novel product, Rhopressa® (netarsudil ophthalmic solution) 0.02%, a once-daily eye drop approved by the U.S. Food and Drug Administration (FDA) for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension, was launched in the United States in April 2018. In clinical trials of Rhopressa®, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain, and conjunctival hemorrhage. More information about Rhopressa®, including the product label, is available at www.rhopressa.com. Aerie’s second novel product for the reduction of elevated IOP in patients with open-angle glaucoma or ocular hypertension, Rocklatan® (netarsudil (0.02%) and latanoprost ophthalmic solution (0.005%), was launched in the United States in May 2019. In clinical trials of Rocklatan®, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain, and conjunctival hemorrhage. More information about Rocklatan®, including the product label, is available at www.rocklatan.com. More information on Aerie Pharmaceuticals is available at www.aeriepharma.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220217005787/en/
Contacts
Media:
Carolyn McAuliffe
cmcauliffe@aeriepharma.com
(949) 526-8733
Investors:
LifeSci Advisors on behalf of Aerie Pharmaceuticals, Inc.
Hans Vitzthum
hans@lifesciadvisors.com
(617) 430-7578
Source: Aerie Pharmaceuticals, Inc.